Geographic Atrophy

Spectri Study

About The Study:

Principal Investigator: Yevgeniy Shildkrot, MD

Sponsored by F. Hoffman-La Roche, the purpose of this multi-center study is to compare the effects of intravitreal injections of lampalizumab versus sham injections, in participants who have geographic atrophy.  This study will also see if people with specific genetic characteristics may have an increased risk of AMD.

All participants will be randomized to one of four study groups.  There is a 2 in 3 chance of being assigned to one of the study drug groups and a 1 in 3 chance of being assigned to the sham injection groups.  The groups are:

  • Group A—10 mg of lampalizumab administered via intravitreal injection every 4 weeks
  • Group B—Sham injection every 4 weeks
  • Group C—10 mg of lampalizuamb administered via intravitreal injection every 6 weeks
  • Group D—Sham injection every 6 weeks

Participants participating in this study will make up to 26 scheduled study visits over a period of 24 months.  Each visit will last anywhere from 2-5 hours.

Key Inclusion Criteria:

  • Age ≥ 50 years
  • BCVA of 20/100 or better in the study eye
  • Presence of geographic atrophy in both eyes
  • Lesion in the study eye measuring ≥ 1 DA and ≤ 7 DA

Key Exclusion Criteria:

  • History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
  • History of prior CNV in either eye
  • Previous laser photocoagulation in the study eye
  • Proliferative diabetic retinopathy in either eye
  • History of previous intravitreal drug delivery
  • Uncontrolled glaucoma in the study eye—IOP ≥ 30 mmHg
  • History of glaucoma filtration surgery

For additional information about the trials or to refer a patient, contact the study coordinators:

  • Ashton Leone, MPH at (434) 243-5737 or
  • Tamika Mercer at (434) 243-2852 or